All UK companies attending BES

UK companies attending Bio-Europe Spring as part of the official delegation

(Click here to search profiles):

booth 56  Almac Group        
booth 34   
booth 35  cddi   

Astex Pharmaceuticals, BIA, Diamond Pharma Services, Domainex, Eden Biodesign, Entrepreneurs Fund, ERA Consulting, Fusion Antibodies, Innova Biosciences, Integrity Life Sciences, NextPharma, Novozymes Biopharma, Oxford Expression Technologies, Penn Pharma, PharmaVentures, PRMA Consulting, Q-Chip, Saccharides Science and Technology, Sera Laboratories, Simbec, Sygnature Discovery, Theryte, Vitrology

UK companies associated with the delegation*:

Alcyomics, Biomoti, Critical Pharmaceuticals, Cyclofluidic, Goldshield Group, Institute of Cancer Research (ICR), Illetrop, Immupharma, Isogenica, Nexus Oncology, Pharmawave, Polytherics, Proimmune, Present Value, Sareum, Selcia, Silence Therapeutics, Warner Chilcott

Other attending UK companies include:

3M Drug Delivery Systems, Advocates Pharmaceutical & Healthcare, Aesica Pharmaceuticals, Alliance Pharmaceuticals, Angel Biotechnology, Antitope, Apex Healthcare Consulting, Aquapharm Biodiscovery, Ark Therapeutics, Astellas Pharma Europe, AstraZeneca, b-neuro, BioFocus, Bioline Reagents, BioMed Central, BioPharm Insight, Birmingham University, Brecon Pharmaceuticals, Bristol-Myers Squibb, BTG International, Cancer Research Technology, Cmed Clinical Services, CMP Therapeutics, Cobra Biologics, College Hill, Coulter Partners, Creabilis SA, Crescendo Pharmarkets, Current Partnering, Cyclacel, Edinburgh BioQuarter, Eisai Europe,  Eli Lilly and Company,  EvaluatePharma,  Evotec UK,  Ferghana Partners, Fujifilm Diosynth Biotechnologies, Future Injection Technologies, Galen,  GE Healthcare, Gen-Probe Life Sciences,  Gerson Lehrman Group, GlaxoSmithKline,  GW Pharmaceuticals, Health Technologies @ Strathclyde University, Heptares Therapeutics, Immune Targeting Systems (ITS),  Immunocore, IMS Health, Innovaro Pharmalicensing, Kent Science Park, Kymab, MedImmune,  Morrison & Foerster, Mundipharma International, MVM Life Science Partners LLP, NDA Group, Norgine, NovaSecta, OBN, One Nucleus, ONO Pharma UK, Onyx Scientific, Oval Medical Technologies, Medimix International, Oxford BioMedica, Oxford BioTherapeutics,  Oxford Pharmascience Group, Patheon, Paul Capital, PharmaWave,  Phase4 Ventures Ltd, Physiomics, Phytopharm plc, PRECOS,  ProPharma Partners,  Proximagen, PsiOxus Therapeutics,  Quay Pharmaceuticals, Quintiles Commercial, Redx Pharma, ReNeuron Group plc, RUSSLAN Clinical Research, Sage Healthcare, Samedan,  Scottish Biomedical, Scottish Development International, Sekisui Diagnostics, Sequani,  Sistemic,  Sphere Fluidics,  Symbiosis Pharmaceutical Services,  Team Consulting,  Technology Catalysts International, Teijin Pharma,  Theradex Europe,  ThomsonReuters, Torreya Partners, UMIP, Venture Market Intelligence, Vernalis R&D,  ViroPharma, Vivacta, Xention.

*BioPartnership Programme members are hyperlinked